![How Will We Interpret Results from the GR-MD- 02 Psoriasis Trial? • NASH & Liver Fibrosis | Galectin Therapeutics How Will We Interpret Results from the GR-MD- 02 Psoriasis Trial? • NASH & Liver Fibrosis | Galectin Therapeutics](http://perspectives.galectintherapeutics.com/wp-content/uploads/2016/04/Screen-Shot-2016-04-28-at-12.16.09-PM-1024x541.png)
How Will We Interpret Results from the GR-MD- 02 Psoriasis Trial? • NASH & Liver Fibrosis | Galectin Therapeutics
Full article: Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
![Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units This PsA Assessment initiative is. - ppt download Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units This PsA Assessment initiative is. - ppt download](https://slideplayer.com/slide/13847028/85/images/25/Psoriasis+Area+Severity+Index+%28PASI%29.jpg)
Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units This PsA Assessment initiative is. - ppt download
![Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study) | The BMJ Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study) | The BMJ](https://www.bmj.com/content/bmj/338/bmj.b1542/F1.large.jpg)
Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study) | The BMJ
![Assessing the severity of psoriasis through multivariate analysis of optical images from non-lesional skin | Scientific Reports Assessing the severity of psoriasis through multivariate analysis of optical images from non-lesional skin | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-65689-4/MediaObjects/41598_2020_65689_Fig1_HTML.png)
Assessing the severity of psoriasis through multivariate analysis of optical images from non-lesional skin | Scientific Reports
![Mean Psoriasis Area and Severity Index (PASI) score in patients treated... | Download Scientific Diagram Mean Psoriasis Area and Severity Index (PASI) score in patients treated... | Download Scientific Diagram](https://www.researchgate.net/publication/23466796/figure/fig2/AS:293870556069889@1447075608680/Mean-Psoriasis-Area-and-Severity-Index-PASI-score-in-patients-treated-with.png)
Mean Psoriasis Area and Severity Index (PASI) score in patients treated... | Download Scientific Diagram
![PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol | The Journal of Rheumatology PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol | The Journal of Rheumatology](https://www.jrheum.org/content/jrheum/45/7/922/F3.large.jpg)
PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol | The Journal of Rheumatology
![The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis | Semantic Scholar The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/206b3763bd2ce81db7cd8b22499cd629438e6d66/4-Table2-1.png)
The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis | Semantic Scholar
![Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab | SpringerLink Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-021-00564-2/MediaObjects/13555_2021_564_Fig3_HTML.png)
Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab | SpringerLink
![JCM | Free Full-Text | Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study JCM | Free Full-Text | Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study](https://www.mdpi.com/jcm/jcm-11-04778/article_deploy/html/images/jcm-11-04778-g001.png)
JCM | Free Full-Text | Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study
![JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study](https://www.mdpi.com/jcm/jcm-09-02170/article_deploy/html/images/jcm-09-02170-g001.png)
JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
Psoriasis Area Severity Index (PASI) assessment of a single body region to represent achievement of PASI 75 and 90 responses wit
![Assessing the severity of psoriasis through multivariate analysis of optical images from non-lesional skin | Scientific Reports Assessing the severity of psoriasis through multivariate analysis of optical images from non-lesional skin | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-65689-4/MediaObjects/41598_2020_65689_Fig4_HTML.png)